FDA Grants Accelerated Approval to NVS Kidney Disease Drug

Novartis (NVS) obtains FDA approval of atrasentan, a potent and selective endothelin A (ETA) receptor antagonist, for the reduction of proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression. The approval was granted on an accelerated basis.The candidate got approval under the brand name Vanrafia.IgAN is a progressive, rare kidney disease. Approximately 50% of patients with persistent proteinuria progress to kidney failure within 10 to 20 years of diagnosi ...